Is AbbVie Stock Too Cheap to Ignore at Today's Price?
Summarize this article with:
By Prosper Junior Bakiny – Dec 11, 2025 at 11:06AMKey PointsSome valuation metrics suggest that AbbVie is a cheap stock. The company's growth prospects through 2030 look attractive.AbbVie is also an excellent dividend stock. These 10 Stocks Could Mint the Next Wave of Millionaires ›NYSE: ABBVAbbVieMarket Cap$398BToday's Changeangle-down(-0.90%) $2.02Current Price$223.16Price as of December 11, 2025 at 12:15 PM ETThe drugmaker has plenty to offer investors.AbbVie (ABBV 0.90%), a pharmaceutical leader, has faced some challenges over the past three years. The company is managing some patent cliffs and clinical setbacks that worried investors and dinged its stock price. Despite all that, the stock still performed well over this period. Yet, there is an argument to be made that AbbVie remains attractively valued and will grow into its valuation over the next five years or so, delivering market-beating returns in the process. Image source: Getty Images. Looking at some key metrics Let's consider two metrics that help make a case for AbbVie's shares being undervalued at current levels. First, the stock trades at 16.8 times forward earnings. That's slightly lower than the 18.3 average for the healthcare sector, and the 22.6 average for the S&P 500. AbbVie's price/earnings-to-growth (PEG ratio) of 0.43 also puts the stock well within the undervalued range. Of course, numbers can't tell us everything. But these two, which are well-respected valuation metrics, at least suggest that AbbVie is too cheap to ignore. ExpandNYSE: ABBVAbbVieToday's Change(-0.90%) $-2.02Current Price$223.16Key Data PointsMarket Cap$398BDay's Range$222.94 - $226.2652wk Range$164.39 - $244.81Volume52KAvg Vol6MGross Margin69.68%Dividend Yield2.91% The growth drivers and the dividend Now, let's turn to the company's operations. AbbVie has a lineup of products across multiple therapeutic areas: Neuroscience, oncology, and, of course, immunology, which is its most important market. The drugmaker has several growth drivers. Two of them, Skyrizi and Rinvoq -- both immunosuppressants -- will be the main ones for the foreseeable future. Combined, they are approved across several indications in immunology, including plaque psoriasis, rheumatoid arthritis, Crohn's disease, and ulcerative colitis. Here's the best part: Neither will lose patent exclusivity anytime soon. So, for the next five years at least, they should help AbbVie's revenue and earnings move consistently in the right direction. What's more, AbbVie won't face any major patent cliff through the end of the 2020s at all, even beyond its two core growth drivers. Meanwhile, we can expect the pharmaceutical leader to expand its lineup through new approvals, given its extensive pipeline, which features several dozen products. Even a handful of approvals or label expansions can have a meaningful effect.Advertisement Lastly, AbbVie is a fantastic income stock. The company is part of the group of Dividend Kings, corporations that have increased their payouts for at least 50 consecutive years (it inherited this designation from when it was still part of Abbott Laboratories back in 2013). AbbVie's "streak" is currently at 54 years. When considering the company's valuation, growth prospects through 2030 (at least), and its excellent dividend program, AbbVie appears to be a no-brainer for income seekers at current prices.About the AuthorProsper Junior Bakiny is a contributing Motley Fool healthcare analyst covering biotechnology, pharmaceuticals, and healthcare stocks.
Before The Motley Fool, Prosper wrote about investing topics ranging from stock market news to private equity for various companies. He holds a master’s degree in corporate finance from the University of Maryland Global Campus.TMFPBakinyRead NextDec 6, 2025 •By Matthew BenjaminThe Pharmaceutical Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.Dec 4, 2025 •By Prosper Junior BakinyCould Buying AbbVie Today Set You Up for Life?Nov 29, 2025 •By David Jagielski, CPA3 High-Yielding Dividend Growth Stocks That Can Generate Passive Income for Your Portfolio for YearsNov 17, 2025 •By Prosper Junior BakinyAbbVie Stock Falls 4% -- What Investors Need to KnowNov 15, 2025 •By Keith SpeightsWant Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.Nov 13, 2025 •By Rachel Warren2 Strong Healthcare Stock Picks for Dividend Investors